Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04477018
Other study ID # 9BN2
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 11, 2017
Est. completion date June 8, 2019

Study information

Verified date July 2020
Source Northumbria University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Iron deficiency is the most prevalent nutritional deficiency worldwide with one in four estimated to be affected by iron deficiency anaemia. Women of reproductive age are at greatest risk for iron deficiency and anaemia due to iron losses during menstruation and childbirth as well as the increased need for iron throughout pregnancy. However, iron deficiency without anaemia is at least twice as common as iron deficiency anaemia with females aged 11-49 at the biggest risk of all. Despite this, it is commonly left undiagnosed. Those who are iron deficient non-anaemic can still suffer from the same common consequences of iron deficiency anaemia; these include unexplained fatigue, mood changes and decreased cognitive performance. It is postulated that for any cognitive and behavioural change to occur, a complementary change in neural functioning is required. A recent cross-sectional study has identified increases in cognitive demand to produce decrements in measures of cognitive performance and increases in brain activity and metabolic measures; the magnitude of such are evidenced to be directly related to iron status. However, such measures do not provide an estimate of overall oxygen consumption that is specific to the brain in order to be able to associate changes in cognitive performance and energy expenditure specifically to the brain itself. The current study aims to investigate the parallel effects of iron supplementation on cerebral haemodynamics and energy metabolism to determine the ability of iron to modulate whole body energy metabolism and utilisation of metabolic substrates at rest and during cognitive demand in a sample of non-anaemic iron deficient and iron sufficient women of reproductive age.


Description:

Each participant will be required to attend the laboratory on four occasions. The first is comprised of a screening/training visit, which will take place in the afternoon for approximately 2.5 hours. This will also be between days 21-28/ the week before onset of their menstrual cycle. If they do not have menstrual bleeds then this appointment can be any afternoon. This will comprise: briefing of requirements of the study; obtaining of informed consent; confirmation of eligibility to take part, including collection of demographic data and health screening, and training on the cognitive and mood measures. The training session will follow standard operating procedures to decrease the chance of learning effects during main trials. Extra training will be given where necessary.

Participants will be required to complete questionnaires based upon food frequency, caffeine consumption and to estimate the number of hours of exercise completed on a weekly basis. A menstrual cycle questionnaire will also be completed to estimate menstrual blood loss and so that participants attend their testing visit during days 7-14 of their cycle. If participants do not have a menstrual cycle due to contraceptive methods, then appointments will be approximately two weeks apart. A finger-prick and venous blood sample will be collected from participants, which will be analysed for iron status. Those whose haemoglobin levels are <120g/L will be advised to seek advice from their GP. Participants who fell into the iron status category of iron sufficient (haemoglobin ≥120 g/L and serum ferritin > 20 µg/L) or non-anaemic iron deficient (haemoglobin ≥120 g/L and serum ferritin ≤ 20 µg/L) will be informed of their eligibility for the intervention study by email or phone between the initial visit and their next. This will include the option to enrol in an additional assessment of neuroimaging and energy metabolism.

For the testing visit, participants will be asked to fast for 12 hours prior to the visit, avoiding intake of all food and drink with the exception of water. They will also be asked to avoid alcohol and refrain from intake of 'over the counter' medication for 24 hours. Participants will arrive at the laboratory at a designated time in the morning. The following procedures will take place prior to cognitive and mood testing:

Review of continued conformity to eligibility criteria Adverse event and concomitant medication assessment Ensure that participant is in good health

Participants will then complete the baseline cognitive and mood assessments. Following this, participants are informed of their iron status and will be briefed regarding the requirements of the intervention study and additional assessment. Following this, informed consent will be obtained prior to starting the additional assessment. Participants will have a frequency domain near-infrared spectroscopy headband attached to the forehead to measure cerebral blood flow at rest for five minutes. Following this, participants will instead have a continuous wave near-infrared spectroscopy headband attached to the forehead to measure cerebral blood flow, and a face mask fitted to measure expired air. Participants will have another five minute rest before completing an additional battery of cognitive tasks for approximately 35-40 minutes. Once complete, participants will be randomised to one of three treatments and be provided with a treatment diary to log treatment consumption and any adverse events experienced.

Participants will return to the laboratory after 8 weeks to exchange treatment bottles and diaries in order to check compliance.

Participants will finally return to the laboratory after a further 8 weeks (16 weeks total). The same procedures will take place prior to cognitive and mood testing as completed at the baseline testing visit, with the addition of finger prick and venous blood sample and weight measurement. Participants will then complete the same cognitive, mood and neuroimaging and energy metabolism assessments as completed during the baseline testing visit.


Recruitment information / eligibility

Status Completed
Enrollment 78
Est. completion date June 8, 2019
Est. primary completion date June 8, 2019
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 18 Years to 49 Years
Eligibility Inclusion Criteria:

- Healthy

- Female

- Aged 18-49 (inclusive)

- Have a BMI of between 18.5-40

- Have an English bank account (required for payment)

Exclusion Criteria:

- Aged under 18 or above 49 years

- BMI lower than 18.5 or higher than 40

- Pre-existing medical condition/illness with some exceptions - please check with researcher

- Blood disorders (including anaemia) or any known active infections

- Current or past breast cancer diagnosis and/or mastectomy

- Smoking or use of any nicotine replacement products e.g. vaping, gum, patches

- Pregnant, trying to get pregnant or breast feeding

- Currently taking any prescription medication with some exceptions - please check with researcher

- Food allergies/sensitivities relevant to the study

- Regular use of dietary/herbal supplements within the last month (defined as more than 3 consecutive days or 4 days in total)

- Use of iron supplements within the past 4 months

- Have donated more than 300ml of blood in the past 3 months

- Have haemoglobin levels below 120g/L

- History of significant head trauma or suffer from frequent migraines that require medication (more than or equal to one per month)

- Learning difficulties, dyslexia, or colour blindness

- Visual impairment that cannot be corrected with glasses or contact lenses

- Currently taking part in any other clinical or nutritional intervention studies or have in the past 4 weeks

- Any health condition that would prevent fulfilment of the study requirements

Study Design


Intervention

Dietary Supplement:
Iron bis-glycinate chelate and vitamin C
28 mg iron; 240 mg vitamin C
Iron bis-glycinate chelate
28 mg iron only
Placebo
Matched placebo

Locations

Country Name City State
United Kingdom Brain, Performance & Nutrition Research Centre, Northumbria University Newcastle Upon Tyne

Sponsors (2)

Lead Sponsor Collaborator
Northumbria University Bayer

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cerebral Blood Flow Near Infrared Spectroscopy outcomes for cerebral blood flow measurement at rest and during cognitive demand 16 weeks
Secondary Serial Subtraction Performance Performance on serial subtractions (3s and 7s) will be assessed as total responses and total errors 16 weeks
Secondary Rapid Visual Information Processing Performance is assessed as accuracy (%), correct reaction time (msec) and false alarms 16 weeks
Secondary Subjective alertness Subjective alertness will be derived from an Alertness visual analogue scale presented following cognitive task performance. Scores range from 0 to 100. Higher scores are indicative of greater feelings of alertness. 16 weeks
Secondary Subjective fatigue Subjective mental fatigue will be derived from a Mental Fatigue visual analogue scale presented following cognitive task performance. Scores range from 0 to 100. Higher scores are indicative of greater feelings of mental fatigue. 16 weeks
Secondary Fat Oxidation Fat oxidation will be assessed through indirect calorimetry at rest and during cognitive demand 16 weeks
Secondary Carbohydrate Oxidation Carbohydrate oxidation will be assessed through indirect calorimetry at rest and during cognitive demand 16 weeks
Secondary Respiratory Energy Ratio Respiratory energy ration will be assessed through indirect calorimetry at rest and during cognitive demand 16 weeks
Secondary Total Energy Expenditure Total energy expenditure will be assessed through indirect calorimetry at rest and during cognitive demand 16 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05563805 - Exploring Virtual Reality Adventure Training Exergaming N/A
Completed NCT03708692 - Menstrual Cycle Phases on Recovery and Cognitive Function
Active, not recruiting NCT04505345 - Virtual Reality Cognitive Training in Alcohol Use Disorder N/A
Completed NCT04430465 - Effects of Wholegrains on Children's Health (KORN) N/A
Completed NCT02915913 - Effects of Exercise Training on Cognitive Function and Neurotrophic Factors in Overweight Adults N/A
Completed NCT01410097 - Physical and Cognitive Function - Look AHEAD Ancillary Study N/A
Completed NCT03826121 - Efficacy and Safety of Sesame Oil Cake Extract on Improvement of Cognitive Function N/A
Recruiting NCT05621278 - Children to Adults Mental and Psychosomatic Health Study (CAMPS)
Completed NCT05498415 - Feasibility, Acceptability, and Efficacy of the Sleep Move Stand Study N/A
Completed NCT03208569 - Anticholinergic Burden - Treatment Optimization
Completed NCT03793777 - The Effect of Aronia Melanocarpa Extract on Cognitive Function N/A
Recruiting NCT05525299 - Reminiscence-Based Life Review on Copying With Existential Suffering Among Older Cancer Survivors N/A
Completed NCT03698123 - Performance Nutrition for Residents and Fellows N/A
Completed NCT04543500 - Self-regulation of Prefrontal Cortex During Emotional Cognitive Control N/A
Recruiting NCT05891977 - Effect of Tomato Paste Consumption on the Microbiota-gut-brain Axis in Healthy Adults N/A
Recruiting NCT05591885 - Nutrilite Memory Builder on the Improvement of Cognitive Function N/A
Active, not recruiting NCT05575752 - Acute Health Effects of High Temperature Exposure N/A
Completed NCT03716609 - Effects of Magnesium Supplementation on Hemodynamic Parameters and Cognitive Function N/A
Completed NCT02763514 - The Effects of DHA- and EPA-enriched Oils on Cognitive Function and Mood N/A
Completed NCT02675621 - Investigation of Acute Mood and Cognitive Performance Effects of Beverages Containing Phenolics in Healthy Adults N/A